http://exhibits.library.stonybrook.edu/mfp/files/original/9f0981900307dec3783ffb664e977b13.pdf 2b0a91a1c60fa3b3b931936f9ef03f21 PDF Text Text July 17, 1995 Worrawat Chanpattana, MD. Department of Psychiatry Srinakarinwiroth University Vajira Hospital, Samsen, Dusit Bangkok, Thailand Dear Dr. Chanpattana, I have read the outline of your proposed study of continuation ECT in interest. There is a need for a prospective study of ECT contrasted with with schizophrenia neuroleptic drugs in schizophrenia. The basis for this belief is the review, now in press in Schizophrenia Bulletin, which I recently completed with Dr. Harold Sackeim; a copy is enclosed. The question which you seek to answer with the design of your study, however, is not central to our present concerns. Most patients are treated with neuroleptics first, and only treatment failures are considered for ECT. In such a group, there would be little justification to continue treatment with a failed compound [such as a neuroleptic]. If you wish to answer the question which intervention reduces relapse rate for longer periods, and at what cost, then patients who failed an adequate neuroleptic trial for schizophrenia could be assigned to receive either a continuation neuroleptic [although an atypical neuroleptic like clozapine would be preferred] contrasted with those treated with ECT [either alone or combined with the atypical neuroleptic]. Such a study would parallel ongoing US studies comparing the relative efficacy and safety of continuation ECT, continuation lithium combined with a tricyclic compared, and lithium alone. It is probably inappropriate to use haloperidol combined with ECT since there are few studies of this combination. Considering the high risk of haloperidol for inducing dyskinesia, it is not favored by many psychiatrists. I am not directly involved in the support by our governmental or private agencies of mental health research, and so cannot answer your query about support. My regards. Sincerely yours, Max Fink, MD. Professor of Psychiatry and Neurology � Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Correspondence Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Correspondence to: Chanpattana, Worrawat Type The nature or genre of the resource Text Identifier An unambiguous reference to the resource within a given context mfp-05-00-033-6-115 Date A point or period of time associated with an event in the lifecycle of the resource 1994 Creator An entity primarily responsible for making the resource <a title="Fink, Max, 1923-" href="http://id.loc.gov/authorities/names/n79039548" target="_blank">Fink, Max, 1923-</a> Subject The topic of the resource Correspondence -- Correspondence Relation A related resource The Max Fink Collection Description An account of the resource Rights Information about rights held in and over the resource <a title="IN COPYRIGHT - EDUCATIONAL USE PERMITTED" href="http://rightsstatements.org/vocab/InC-EDU/1.0/" target="_blank">IN COPYRIGHT - EDUCATIONAL USE PERMITTED</a> Source A related resource from which the described resource is derived Special Collections and University Archives, University Libraries. Stony Brook University Libraries (State University of New York). Language A language of the resource en-US Format The file format, physical medium, or dimensions of the resource application/pdf Publisher An entity responsible for making the resource available Contributor An entity responsible for making contributions to the resource Correspondence